← Human Trials & Peer-Reviewed Studies
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults
Plain-language guide to PMID 29599478 (2018): double-blind randomized controlled trial study of NAD+.
Key Facts
- PMID
- 29599478
- Journal
- Nature communications
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Martens CR et al. (8 authors)
- DOI
- 10.1038/s41467-018-03421-7
- Registered trial
- NCT04614714, NCT06521307
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of NAD+, published as a randomized controlled trial.
Who Took Part
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
The participants were allocated by chance, so the NAD+ group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on NAD+, so expectations could not easily colour the readings.
Some participants received a placebo instead of NAD+, giving a reference point.
In the crossover set-up each of the participants took both NAD+ and the comparison in turn, acting as their own control.
What Was Measured
PubMed files the paper under topics including Blood Pressure, Caloric Restriction, NAD, Niacinamide, Pyridinium Compounds and Vascular Stiffness.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of NAD+.
The publication is from 2018 (Nature communications), a journal based in England.
More context: the NAD+ compound page, all human trials.
Our Notes on the Compound
NAD+: The coenzyme that accepts electrons at complex I.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.